Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OH8W
|
|||
| Former ID |
DIB015698
|
|||
| Drug Name |
Visilizumab
|
|||
| Synonyms |
Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Graft-versus-host disease [ICD-11: 4B24; ICD-9: 279.5] | Phase 3 | [1] | |
| Company |
PDL BioPharma Inc; PDL BioPharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Regulatory protein unspecific (RGP) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00502294) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis. U.S. National Institutes of Health. | |||
| REF 2 | Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.